Provided by Tiger Trade Technology Pte. Ltd.

Ocugen

0.9984
+0.00490.49%
Post-market: 1.010.0113+1.13%19:25 EDT
Volume:9.09M
Turnover:9.01M
Market Cap:337.97M
PE:-3.91
High:1.02
Open:0.9970
Low:0.9700
Close:0.9935
52wk High:2.73
52wk Low:0.9700
Shares:338.52M
Float Shares:327.56M
Volume Ratio:0.52
T/O Rate:2.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2551
EPS(LYR):-0.2260
ROE:-660.00%
ROA:-48.44%
PB:-20.41
PE(LYR):-4.42

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Eli Lilly, Space stocks, Anixa Biosciences

Reuters
·
Apr 02

Sector Update: Health Care Stocks Advance Pre-Bell Wednesday

MT Newswires Live
·
Apr 01

Ocugen completes dosing in GARDian3 trial

TIPRANKS
·
Apr 01

BUZZ-U.S. STOCKS ON THE MOVE-Seagate, nCino, Zymeworks

Reuters
·
Apr 01

BUZZ-Ocugen rises after finishing patient dosing in late-stage eye gene therapy trial

Reuters
·
Apr 01

Ocugen completes dosing in Phase 2/3 Stargardt gene therapy trial ahead of schedule

Reuters
·
Apr 01

Ocugen Inc. Stock Rises Tuesday, Outperforms Market

Dow Jones
·
Apr 01

Ocugen Inc. Stock Slips 6.4%, Underperforms Market

Dow Jones
·
Mar 31

Ocugen Inc. Stock Sheds 4.6%, Underperforms Market

Dow Jones
·
Mar 28

Assessing Ocugen (OCGN) Valuation After Recent Share Price Volatility And Long Term Momentum

Simply Wall St.
·
Mar 27

Canaccord Genuity Sticks to Its Buy Rating for Ocugen (OCGN)

TIPRANKS
·
Mar 26

Ocugen Inc. Stock Rises Wednesday, Outperforms Market

Dow Jones
·
Mar 26

Ocugen: Encouraging Phase 2 OCU410 Data in Geographic Atrophy Underpin Buy Rating and Long-Term Upside Potential

TIPRANKS
·
Mar 26

Is Ocugen (OCGN) Pricing Make Sense After Its Volatile Multi‑Year Share Price Swings

Simply Wall St.
·
Mar 25

Ocugen Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 25

Ocugen price target raised to $10 from $7 at H.C. Wainwright

TIPRANKS
·
Mar 25

Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday

MT Newswires Live
·
Mar 24

Ocugen Reports Positive Phase 2 Trial Data For Eye Disease Therapy

MT Newswires Live
·
Mar 24

BUZZ- Ocugen rises as gene therapy slows vision loss in advanced eye disease trial

Reuters
·
Mar 24

Ocugen announces 12-month data from ArMaDa clinical trial of OCU410

TIPRANKS
·
Mar 24